Amiloride
As of the edition of 20 October 2026, Amiloride is a small molecule: marketed, first approved in 1975 (ES); acts on SCNN1A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Midamor
- First approved
- 1 December 1975 (ES)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- AA PHARMA INC; 5 holders in all
- Registered trials
- 36, 3 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SCNN1A | Epithelial sodium channel subunit alpha | P37088 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 6 | 0 | 1 |
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 6 | 2 | 4 | 0 |
| Phase 3 | 9 | 6 | 0 | 1 |
| Phase 4 | 8 | 5 | 1 | 0 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Padagis | Acquired holder | 2021 to now |
| Merck & Co. | Earlier holder |